Global Challenges – Local Solutions #ICID2020
20-23 FEBRUARY 2020
KUALA LUMPUR, MALAYSIA – KUALA LUMPUR CONVENTION CENTRE
The 19th ICID features an expanded range of sessions by bringing the One Health aspect to the world of clinical infectious diseases and microbiology. The One Health Concept recognizes the commonality of human, environmental and animal health and is critical to understanding, managing and preventing emerging and re-emerging infectious diseases globally. From antimicrobial resistance, Nipah virus and rabies to the effects of climate change, loss of biodiversity, and political instability on infectious diseases, looking through the One Health lens will provide invaluable insights across species and specialties. Connect with colleagues from a wide range of countries and specialties to exchange knowledge, create new ideas and start collaborations.
Enterovirus Infections in Asia Pacific – Critical Updates
Room: 304 & 305
Friday, February 21, 2020, 14:00 – 15:30 hrs
- Asia-Pacific Network for Enterovirus Surveillance Overview and Development of Enterovirus A71 Vaccines – M. Lee (Taiwan)
Laboratory Diagnosis and Management of Enterovirus Infections – Y. F. Chan (Malaysia)
Genetic and Antigenic Evolution of Enteroviruses in Asia Pacific – J. Phuenpa (Thailand)
Enteroviruses (EV), the major pathogens of hand, foot, and mouth disease (HFMD) and herpangina, affectmillions of children each year. Most human enteroviruses cause self-limited infections except polio-viruses, enterovirus A71 (EV-A71), enterovirus D68 (EV-D68), and several echoviruses (Echo) and cox-sackieviruses (CV). Especially, EV-A71 has repeatedly caused large-scale outbreaks in the Asia-Pacificregion since 1997. Some Asian countries have experienced cyclical outbreaks of severe EV-A71 infectionsand initiated development of EV-A71 vaccines. Five EV-A71 vaccine candidates have been clinically eval-uated and three of them were approved for marketing in China.
Li-Min Huang, Cheng-Hsun Chiu, Nan-Chang Chiu, Chien-Yu Lin, Ming-Ta Li, Tsun-Yung Kuo, Yi-Jen Weng, Erh-Fang Hsieh, I-Chen Tai
Background: To ﬁght against enterovirus A71 (EV-A71)-associated diseases, initiated in Taiwan focusing on two-month-old infants.
Methods: We conducted a phase II, double-blind, randomised, placebo-controlled study on infants and children aged two months to 11 years. This study was conducted in 4 parts (2a, 2b, 2c, and 2d) with age de-escalation sequentially. Two doses were administered with a 28-day or 56-day interval. Participants aged two months to (<)two years received a booster dose at one year after the ﬁrst dose. During the surveillance period, solicited adverse events (AEs) and unsolicited AEs were recorded for safety evaluation. Blood samples were collected for neutralising antibody assay at various times. Immune persistence and booster effects were also assessed.
Results: A total of 363 children completed the study. Most AEs were mild and unrelated to treatment. No vaccine-related serious adverse events (SAEs) were reported. Geometric mean titres (GMTs) of serum neutralising antibody titres increased profoundly. Most participants in the vaccine groups achieved deﬁned seroprotection (neutralization titre 1:32) after the second vaccination and persisted for two years. Furthermore, the EV-A71 vaccine could provide a cross-reaction against other EV-A71 strain geno-types: B5, C4a, C4b, and C5.
Conclusions: The mid dose of the EV-A71 vaccine elicited high immune response and were tolerable in participants aged between two months and 11 years in all dosing groups.
Sourced from Medigen Vaccine Corporation, Taiwan
This document demonstrates the incidence of enterovirus reported by APNES member organizations from January 1 to December 31, 2018.
Download : 2018 Enterovirus Surveillance Annual Report (Jan – Dec)
This workshop was hold by NHRI on May 2, 2019 at Howard Civil Service International House, Room 101.
The Research Institute for Tropical Medicine (RITM) had its humble beginnings soon after the culmination of over a decade of negotiations between the governments of the Philippines and Japan for the establishment of a tropical medicine research center. RITM was tasked to plan and implement research programs for infectious and tropical diseases.
The original building facilities of RITM, which included a laboratory wing and a 50-bed hospital for patients with infectious diseases requiring tertiary care, were inaugurated on April 23, 1981.Continue reading
APNES team would like to wish you a happy and healthy holiday season, and a happy New Year!
This document is the summary of enterovirus surveillance updates from the APNES meeting held on September 29, 2018 in Taipei, Taiwan.
Sourced from CDC, US https://www.cdc.gov/non-polio-enterovirus/outbreaks-surveillance.html
Information on cases and outbreaks of enterovirus infection is collected in the United States using two surveillance systems:
- National Respiratory and Enteric Virus Surveillance System (NREVSS): a voluntary, laboratory-based surveillance system that has included enterovirus reporting since July 2007. This system is used to track the number of enterovirus tests that are performed and the proportion that are positive, by specimen type, location, and when they were collected. Serotyping, demographic data, and clinical data are not reported.
- National Enterovirus Surveillance System (NESS): a passive, voluntary, laboratory-based system that collects basic data on specimens positive for enterovirus or human parechovirus, including serotype. NESS has been collecting data since the 1960s.